CervoMed Shares Drop Over 20% Despite Early Biomarker Progress in Dementia Trial
CervoMed Inc. (NASDAQ:CRVO) released preliminary 12-week data from its 36-week Phase 2a trial evaluating neflamapimod for nonfluent variant primary progressive aphasia, a rare form of frontotemporal dementia. Despite reporting early biological progress, the company's shares fell sharply in trading.
During the initial open-label period, patients treated with neflamapimod saw an average reduction of approximately 3.1 pg/mL in neurofilament light chain, a key plasma biomarker linked to nerve cell damage. For a subgroup of 13 patients with higher baseline biomarker levels, the average reduction reached 5.7 pg/mL. The treatment was generally well tolerated with no new safety issues, though one participant withdrew after experiencing elevated liver enzymes that later normalized.
Researchers will continue monitoring the 25-patient study through its full 36-week duration. The trial includes a 24-week open-label treatment phase followed by a 12-week randomized withdrawal period, where half of the participants will switch to a placebo to evaluate clinical efficacy and drug safety.
Key points
- CervoMed Inc. (NASDAQ:CRVO) shares fell more than 20% following initial Phase 2a clinical trial results.
- Neflamapimod led to an average decrease of 3.1 pg/mL in a plasma biomarker associated with nerve damage over 12 weeks.
- The trial drug was generally well tolerated, with one participant exiting due to elevated liver enzymes that resolved after stopping treatment.
- The 36-week study will conclude with a 12-week randomized withdrawal period comparing neflamapimod against a placebo.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did CervoMed stock drop?
CervoMed Inc. shares fell over 20% despite reporting positive early biomarker reductions from a Phase 2a trial testing neflamapimod in a rare form of dementia.
What is neflamapimod being tested for?
Neflamapimod is being evaluated to treat nonfluent variant primary progressive aphasia, a rare subtype of frontotemporal dementia affecting speech and grammar.
What were the key findings from the 12-week trial data?
Patients experienced an average drop of 3.1 pg/mL in plasma neurofilament light chain, a key marker of nerve cell damage, with no new safety concerns identified.